Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹2,377 Cr
₹32.9 Cr vs Jul 2019
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In August 2019 it disclosed 18 stocks worth ₹2,377 Cr, up ₹32.9 Cr from Jul 2019. Its largest positions were Sun Pharmaceutical Industries Limited (12.3%), Divi's Laboratories Limited (10.3%), Cipla Limited (8.5%); the ten largest together made up 78.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 80.6% of its equity. Cash and debt stood at 0.6%. Compared with Jul 2019 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
97%
Top-10 weight is higher than 97% of peers
Breadth
5%
Holds more stocks than 5% of peers
Cash
9%
Holds more cash than 9% of peers
What these mean: concentration · cash
Holdings in August 2019
Download CSVEvery line the fund disclosed, with the change against Jul 2019. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 12.32% | up 0.48 pts | ₹293 Cr | up ₹15.4 Cr | Added |
| Divi's Laboratories Limited | 10.26% | down 0.20 pts | ₹244 Cr | down ₹1.3 Cr | Trimmed |
| Cipla Limited | 8.55% | down 1.01 pts | ₹203 Cr | down ₹20.9 Cr | Trimmed |
| Aurobindo Pharma Limited | 8.34% | up 0.30 pts | ₹198 Cr | up ₹9.7 Cr | Added |
| Lupin Limited | 7.17% | down 0.33 pts | ₹170 Cr | down ₹5.5 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 6.99% | up 0.40 pts | ₹166 Cr | up ₹11.8 Cr | Added |
| Abbott India Limited | 6.75% | up 0.49 pts | ₹160 Cr | up ₹13.8 Cr | Added |
| Syngene International Limited | 6.53% | up 0.07 pts | ₹155 Cr | up ₹3.9 Cr | Added |
| Fortis Healthcare Limited | 5.95% | up 0.12 pts | ₹142 Cr | up ₹4.7 Cr | Added |
| Sanofi India Limited | 5.82% | down 0.07 pts | ₹138 Cr | up ₹19 L | Held |
| Biocon Limited | 5.36% | up 0.13 pts | ₹127 Cr | up ₹4.9 Cr | Added |
| Alkem Laboratories Limited | 5.16% | up 0.15 pts | ₹123 Cr | up ₹5.1 Cr | Added |
| Thyrocare Technologies Limited | 4.22% | up 0.16 pts | ₹100 Cr | up ₹5.1 Cr | Added |
| Zydus Lifesciences Limited | 2.39% | down 0.06 pts | ₹56.9 Cr | down ₹64 L | Trimmed |
| Narayana Hrudayalaya Limited | 1.49% | up 0.07 pts | ₹35.4 Cr | up ₹2 Cr | Added |
| FDC Limited | 0.95% | up 0.02 pts | ₹22.5 Cr | up ₹85 L | Added |
| Indoco Remedies Limited | 0.67% | down 0.10 pts | ₹15.8 Cr | down ₹2.1 Cr | Trimmed |
| Cash, TREPS & receivables | 0.63% | down 0.56 pts | ₹14.9 Cr | down ₹12.8 Cr | Trimmed |
| Healthcare Global Enterprises Limited | 0.46% | down 0.06 pts | ₹10.9 Cr | down ₹1.2 Cr | Trimmed |
What changed, Jul 2019 to Aug 2019
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Sun Pharmaceutical Industries Limitedup ₹15.4 Cr (+0.48% pts)
- Abbott India Limitedup ₹13.8 Cr (+0.49% pts)
- Dr. Reddy's Laboratories Limitedup ₹11.8 Cr (+0.40% pts)
- Aurobindo Pharma Limitedup ₹9.7 Cr (+0.30% pts)
- Alkem Laboratories Limited ₹5.1 Cr (+0.15% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jul 2019, the weight rose most in Healthcare Services (+0.3 pts), and fell most in Pharmaceuticals & Biotechnology (−0.1 pts) and Pharmaceuticals (−0.1 pts).
- Healthcare Services18.5% → 18.8%+0.3 pts
- Pharmaceuticals & Biotechnology80.7% → 80.6%−0.1 pts
- Pharmaceuticals0.8% → 0.7%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Aug 2016 | Aug 2018 | Feb 2019 | May 2019 | Jul 2019 | Aug 2019 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 83.6% | 82.1% | 81.2% | 80.7% | 80.7% | 80.6% |
| Healthcare Services | 14.7% | 16.9% | 18.1% | 18.5% | 18.5% | 18.8% |
| Pharmaceuticals | 1.7% | 0.9% | 0.7% | 0.8% | 0.8% | 0.7% |
Allocation in Aug 2019change vs Jul 2019
- Pharmaceuticals & Biotechnology (12)80.6%▼ 0.1 pts
- Healthcare Services (5)18.8%▲ 0.3 pts
- Pharmaceuticals (1)0.7%▼ 0.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Aug 2019
0.6%
▼ 0.6 pts vs Jul 2019
- Cash alone
- 0.6%
- cash and net receivables
- A year earlier
- 5.3%
- Aug 2018 · now ▼ 4.7 pts
- Last 12 months
- 0.2% – 4.4%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.